Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eledon Pharmaceuticals (Nasdaq: ELDN) will present 24-month follow-up data from eight patients in a Phase 1b long-term extension evaluating tegoprubart in de novo kidney transplant recipients at the American Society of Transplant Surgeons Winter Symposium, January 23–25, 2026.
Key results from the eight-patient cohort: no biopsy-proven acute rejection, no graft loss, no deaths, no new-onset diabetes mellitus, and no de novo donor-specific antibody formation during the study period. Mean eGFR rose from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months. Poster #62 will be presented January 23, 2026; the poster will be posted in the company's Investors section after the presentation.
Positive
- No biopsy-proven acute rejection reported during 24 months
- No graft loss, deaths, new-onset diabetes, or de novo DSA observed
- Mean eGFR increased from 67.0 to 74.2 mL/min/1.73 m² (12→24 months)
Negative
- Very small cohort of only eight patients limits generalizability
- Single-arm Phase 1b design lacks a randomized control group
Details
News Market Reaction – ELDN
On Jan 23, the day this news came out, ELDN closed 4.04% below the previous close.
Data tracked by StockTitan Argus for the Jan 23 session.
Key Figures
- Phase 1b participants
- 8 patients
- Long-term extension in kidney transplantation
- eGFR at 12 months
- 67.0 mL/min/1.73 m²
- Mean eGFR in Phase 1b extension
- eGFR at 24 months
- 74.2 mL/min/1.73 m²
- Mean eGFR in Phase 1b extension
- Follow-up duration
- 24 months
- Long-term tegoprubart kidney transplant data
- 12-month timepoint
- 12 months
- Baseline comparison for eGFR change
Historical Context
-
Outlined 2025 progress, Phase 2 BESTOW data, financing and 2026 tegoprubart plans.
-
Announced CEO fireside chat at major healthcare conference with webcast access.
-
Reported first six type 1 diabetes patients achieving and maintaining insulin independence.
-
Q3 loss update plus BESTOW data alongside dilutive underwritten public offering.
-
Priced ~$50M offering of common stock and pre-funded warrants at set terms.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
phase 1b medical
estimated glomerular filtration rate (egfr) medical
biopsy-proven acute rejection medical
de novo donor-specific antibody medical
anti-cd40l antibody medical
immunosuppression regimen medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Data from eight participants continue to support safety and tolerability profile of tegoprubart
Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months
IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23–25, 2026, in Scottsdale, Arizona.
There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months.
Details on the poster presentation are below:
Title: Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen
Poster: #62
Session Title: Poster Session B
Date: Friday, January 23, 2026, from 5:45 - 7:15 p.m. PT
Following the presentation, a copy of the poster will be available in the Investors section of the Company’s website at https://ir.eledon.com/news-and-events/publications-and-presentations.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to establish and maintain proper and effective internal control over financial reporting and other risks disclosed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 14, 2025. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.